Dr. Regina Hodits

Dr. Regina Hodits

General Partner

Knowing is not enough; we must apply. Willing is not enough; we must do.

— Johann Wolfgang von Goethe

Biography

Regina is a General Partner at Wellington Partners and represents the Wellington funds on the Boards of Endostim, G-Therapeutics, Themis, Rigontec, Middle Peak Medical, Ayoxxa and Atopix. She was a founding investor in Sapiens, which was sold to Medtronic, and an external director at GSK's Respiratory TA Board. Since joining the industry in 2000, she has become an influential investor in the European venture capital industry, focusing on early-stage and growth deals in Life Sciences.

Regina led the life sciences efforts of Atlas Venture in Europe, a leading transatlantic venture capital firm, until January 2010. She was the founding investor in Bicycle Therapeutics, F-star, and Jenavalve. Regina served on several Boards, including the Board of U3 Pharma, which was acquired by Daiichi Sankyo, Nitec Pharma (now part of Horizon Pharma NASDAQ HZPN), Egalet (NASDAQ: EGLT), and Novamed, which was acquired by SciClone (NASDAQ SCLN) in 2010.

Before, Regina worked for Apax Partners and was closely involved in investments such as Genmab and Silence Therapeutics. She started to build her extensive network in the global healthcare industry during her tenure at McKinsey from 1997 to 2000. In the 90s, Regina gained intial insights into the fast-growing biotech sector as post-doctoral researcher at the MRC Cambridge UK, where she collaborated with emerging UK biotech companies. Regina studied chemical engineering in Vienna and holds a Ph.D. in biochemistry.